Tag: BioCina

BioCina Pty Ltd, a global Contract Development and Manufacturing Organisation (CDMO), has launched a comprehensive manufacturing program for RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care. 

BioCina, a biologics Contract Development and Manufacturing Organisation (CDMO), has joined hands with NovaCina, a global fill-and-finish CDMO, to establish a strategic alliance aimed at offering integrated drug substance and drug product solutions for biologics developers.

Australian contract development and manufacturing organisation (CDMO) BioCina has received an AUD 5 million grant under the Federal Government's Medical Research Future Fund (MRFF) Grants scheme to develop enabling technologies for the manufacture of precision mRNA vaccines.

Australian contract development and manufacturing organisation (CDMO) BioCina has appointed Mark Womack as the chief executive officer who will be responsible for the continued growth, commercial strategy and organisational culture of the company.

GPN Vaccines, a South Australian biotech company, has successfully developed a new universal vaccine that targets a pneumonia-causing bacterium.  Developed in collaboration with the University...

Human trials will commence this week on a novel Covid-19 vaccine designed by University of Adelaide researchers and manufactured at the hi-tech BioCina facility...

University of Adelaide has unveiled a plan that could see Australia achieve total COVID-19 vaccine self-reliance within a year. The University announced a partnership with...